NYSE: HIMS Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Hims & Hers Health, Inc. (NYSE: HIMS) Investors with Significant Losses to Contact the Firm
RADNOR, Pa.--(BUSINESS WIRE)--The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of Hims & Hers Health, Inc. (NYSE: HIMS) ('Hims & Hers').
On June 23, 2025, during pre-market hours, the pharmaceutical company Novo Nordisk announced it would no longer provide Hims & Hers with direct access to its FDA-approved weight loss drug Wegovy through NovoCare Pharmacy due to concerns about illegal mass compounding and deceptive marketing by Hims & Hers. Specifically, Novo Nordisk explained that Hims & Hers allegedly failed to comply with laws prohibiting mass sales of compounded drugs and disseminated 'deceptive marketing that put patient safety at risk."
On this news, Hims and Hers stock price fell over 20% during intraday trading on June 23, 2025.
If you are a Hims & Hers investor and would like to learn more about our investigation, please CLICK HERE to fill out our online form or contact Kessler Topaz Meltzer & Check, LLP: Jonathan Naji, Esq. (484) 270-1453 or E-mail at info@ktmc.com. You can also click on the following link or paste it in your browser: https://ktmc.com/hims-hers-health-inc-investigation?utm_source=Businesswire&utm_medium=PR
Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country involving securities fraud, breaches of fiduciary duties and other violations of state and federal law. Kessler Topaz Meltzer & Check, LLP is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world. The firm represents investors, consumers and whistleblowers (private citizens who report fraudulent practices against the government and share in the recovery of government dollars). For more information about Kessler Topaz Meltzer & Check, LLP, please visit www.ktmc.com.
May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
35 minutes ago
- Yahoo
B&G Foods (NYSE:BGS) Has Some Way To Go To Become A Multi-Bagger
There are a few key trends to look for if we want to identify the next multi-bagger. Firstly, we'd want to identify a growing return on capital employed (ROCE) and then alongside that, an ever-increasing base of capital employed. Put simply, these types of businesses are compounding machines, meaning they are continually reinvesting their earnings at ever-higher rates of return. However, after investigating B&G Foods (NYSE:BGS), we don't think it's current trends fit the mold of a multi-bagger. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. For those who don't know, ROCE is a measure of a company's yearly pre-tax profit (its return), relative to the capital employed in the business. Analysts use this formula to calculate it for B&G Foods: Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities) 0.073 = US$200m ÷ (US$3.0b - US$229m) (Based on the trailing twelve months to March 2025). Thus, B&G Foods has an ROCE of 7.3%. In absolute terms, that's a low return and it also under-performs the Food industry average of 10%. Check out our latest analysis for B&G Foods Above you can see how the current ROCE for B&G Foods compares to its prior returns on capital, but there's only so much you can tell from the past. If you'd like, you can check out the forecasts from the analysts covering B&G Foods for free. There hasn't been much to report for B&G Foods' returns and its level of capital employed because both metrics have been steady for the past five years. It's not uncommon to see this when looking at a mature and stable business that isn't re-investing its earnings because it has likely passed that phase of the business cycle. So unless we see a substantial change at B&G Foods in terms of ROCE and additional investments being made, we wouldn't hold our breath on it being a multi-bagger. On top of that you'll notice that B&G Foods has been paying out a large portion (113%) of earnings in the form of dividends to shareholders. Most shareholders probably know this and own the stock for its dividend. In a nutshell, B&G Foods has been trudging along with the same returns from the same amount of capital over the last five years. It seems that investors have little hope of these trends getting any better and that may have partly contributed to the stock collapsing 74% in the last five years. All in all, the inherent trends aren't typical of multi-baggers, so if that's what you're after, we think you might have more luck elsewhere. On a final note, we found 2 warning signs for B&G Foods (1 doesn't sit too well with us) you should be aware of. While B&G Foods may not currently earn the highest returns, we've compiled a list of companies that currently earn more than 25% return on equity. Check out this free list here. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Novo Nordisk announces WeightWatchers collaboration for Wegovy
Novo Nordisk (NVO) said it expanded patient access to Wegovy through a new collaboration with WeightWatchers, beginning July 1. WeightWatchers will work with CenterWell Pharmacy as the dispensing pharmacy managing prescription fulfilment and delivery for NovoCare Pharmacy. 'By extending access to Wegovy through their integrated support system, WeightWatchers aims to provide patients with a more streamlined experience, along with convenient access to FDA-approved medication with the lifestyle support shown to improve outcomes,' the company said. Starting on July 1, Novo Nordisk is also introducing a new cash-offer price of $299 available through July 31. This $299 introductory price is available for self-paying patients who are new to the Wegovy savings offer or those who have not previously filled a prescription through NovoCare Pharmacy. This builds on the previous $199 Wegovy cash-offer patient price that expires on June 30, Novo added. Patients who redeemed the $199 Wegovy savings offer between May 22 and June 30, will be eligible for the $299 price on one fill between July 1 and July 31. For subsequent months, self-paying patients will pay $499 per month. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on NVO: Disclaimer & DisclosureReport an Issue Is the Hims & Hers Stock (HIMS) Crash a Hidden Buying Opportunity? Citi sees tiered orforglipron pricing $15B opportunity for Eli Lilly Needham Downgrades Hims & Hers Stock (HIMS) on Novo Nordisk Fiasco. Wall Street Sees Legal Risks California seeks to cut Medicaid coverage for weight loss drugs, Bloomberg says Hims & Hers litigation risk 'back on the table', says Truist Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
When Should You Buy Ford Motor Company (NYSE:F)?
Ford Motor Company (NYSE:F) led the NYSE gainers with a relatively large price hike in the past couple of weeks. The recent rally in share prices has nudged the company in the right direction, though it still falls short of its yearly peak. With many analysts covering the large-cap stock, we may expect any price-sensitive announcements have already been factored into the stock's share price. However, what if the stock is still a bargain? Let's take a look at Ford Motor's outlook and value based on the most recent financial data to see if the opportunity still exists. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. Good news, investors! Ford Motor is still a bargain right now. Our valuation model shows that the intrinsic value for the stock is $13.76, which is above what the market is valuing the company at the moment. This indicates a potential opportunity to buy low. However, given that Ford Motor's share is fairly volatile (i.e. its price movements are magnified relative to the rest of the market) this could mean the price can sink lower, giving us another chance to buy in the future. This is based on its high beta, which is a good indicator for share price volatility. Check out our latest analysis for Ford Motor Future outlook is an important aspect when you're looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Buying a great company with a robust outlook at a cheap price is always a good investment, so let's also take a look at the company's future expectations. Ford Motor's earnings growth are expected to be in the teens in the upcoming years, indicating a solid future ahead. This should lead to robust cash flows, feeding into a higher share value. Are you a shareholder? Since F is currently undervalued, it may be a great time to accumulate more of your holdings in the stock. With a positive outlook on the horizon, it seems like this growth has not yet been fully factored into the share price. However, there are also other factors such as capital structure to consider, which could explain the current undervaluation. Are you a potential investor? If you've been keeping an eye on F for a while, now might be the time to enter the stock. Its buoyant future outlook isn't fully reflected in the current share price yet, which means it's not too late to buy F. But before you make any investment decisions, consider other factors such as the strength of its balance sheet, in order to make a well-informed investment decision. If you want to dive deeper into Ford Motor, you'd also look into what risks it is currently facing. When we did our research, we found 2 warning signs for Ford Motor (1 is concerning!) that we believe deserve your full attention. If you are no longer interested in Ford Motor, you can use our free platform to see our list of over 50 other stocks with a high growth potential. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
